KPTI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KPTI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:
1. GuruFocus internally developed valuations of the stock, such as GF valuation.Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.
Based on those aspects listed above, GuruFocus believes the risk assessment of Karyopharm Therapeutics is: High Risk: High uncertainty.
For the Biotechnology subindustry, Karyopharm Therapeutics's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Karyopharm Therapeutics's Risk Assessment distribution charts can be found below:
* The bar in red indicates where Karyopharm Therapeutics's Risk Assessment falls into.
Karyopharm Therapeutics (NAS:KPTI) Risk Assessment Explanation
Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:
(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.
Thank you for viewing the detailed overview of Karyopharm Therapeutics's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.
Richard A. Paulson | director, officer: President and CEO | 85 WELLS AVENUE, NEWTON MA 02459 |
Garen G Bohlin | director | C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER STREET, WALTHAM MA 02451 |
Michael Mason | officer: EVP, CFO, Treasurer | 300 3RD STREET, CAMBRIDGE MA 02142 |
Michael Mano | officer: SVP, General Counsel&Secretary | 85 WELLS AVENUE, SUITE 210, NEWTON MA 02459 |
Sohanya Roshan Cheng | officer: SVP Sales & Commercial Ops | C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, NEWTON MA 02459 |
Zhen Su | director | 85 WELLS AVENUE, SUITE 210, NEWTON MA 02459 |
Stuart Poulton | officer: EVP, Chief Development Officer | 85 WELLS AVENUE, NEWTON MA 02459 |
Reshma Rangwala | officer: EVP & Chief Medical Officer | RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098 |
Stephen Mitchener | officer: SVP, Chief Business Officer | C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Deepika Pakianathan | director | 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402 |
Ran Frenkel | officer: EVP, WW Development Operations | C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, 2ND FLOOR, NEWTON MA 02459 |
Jatin Shah | officer: EVP, Chief Medical Officer | C/O KARYOPHARM THERAPEUTICS, INC., 85 WELLS AVENUE, NEWTON MA 02459 |
Sharon Shacham | officer: C.S.O & Pres. of Res & Develop | C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459 |
Michael Kauffman | director, officer: President, C.E.O., C.M.O. | C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459 |
Peter Honig | director | 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037 |
From GuruFocus
By PRNewswire • 11-14-2023
By PRNewswire • 07-25-2023
By PRNewswire • 10-26-2023
By PRNewswire • 09-01-2023
By PRNewswire PRNewswire • 06-01-2023
By PRNewswire PRNewswire • 06-01-2023
By PRNewswire • 06-28-2023
By PRNewswire • 09-05-2023
By PRNewswire PRNewswire • 05-01-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.